Unit sales of pharmaceutical and biologic products

Negotiated with rebates and tiered discounts

19.7% Gross Margin (Thin (<20%))

Product sales

Physician prescription, formulary placement, payer negotiation

Enterprise (health systems, government programs, managed care)

Government health programs (Medicare, Medicaid, VA)

Biopharmaceutical manufacturer & specialty distributor

Contract research and development services / collaboration partner

Moderate

Linear

International with significant U.S. focus

Very High

Low

Yes

High

Moderate

Moderate

No

High

4.9% Return on Assets (Excellent)

Defensive

Moderate

-19.73x Total Debt / Equity (Negative equity)

Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Sublinear

N-A

High

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.25 (HIL — ~25% of characteristic roles agent-automatable)

Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0001551152

ABBV

2.0% CapEx / Revenue (Low-CapEx Asset-Light)

Moderate

active_enforcement_matters,antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,capital_return_posture,channel_inventory_exposure,churn_vulnerability_index,currency_risk_exposure,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,cyber_framework_alignment,cyber_incident_materiality,cyber_oversight_body,data_sovereignty_risk,employee_headcount,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,hedging_program_scope,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,key_person_dependency,liquidity_sufficiency_assertion,marginal_cost_of_growth,market_structure,monetization_vector,named_competitors,network_effect_present,pricing_architecture,pricing_power_rating,product_revenue_concentration,purchase_commitment_rigidity,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,seasonality_pattern,supply_chain_dependency,switching_cost_profile,trade_restriction_exposure,vendor_lock_dependency_score

0

1

-32710

2026-08-14

2026-10-03T13:39|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

Not disclosed in filing

Not stated

Not explicitly named by company name

Fragmented

Skyrizi and Rinvoq combined = 42% of total net revenues in 2025

Dividend+Buyback; $11.7 billion dividends in 2025, $606 million share repurchases in 2025

Moderate; tariffs and trade policy risk to supply chains and costs

Mild; no significant seasonality disclosed

Affirmed

Moderate; three U.S. wholesale distributors control substantially all pharmaceutical sales

No specific named current consent orders or enforcement actions disclosed

Low; no material unconditional purchase commitments disclosed

No

NIST CSF

Audit Committee; full board reviews cybersecurity risks regularly

Moderate; Euro, Canadian dollar, Japanese yen, British pound primary exposures; approximately 24% of revenues outside U.S.

FX forwards on EUR, CAD, JPY, GBP revenues and net investment hedges; interest rate swaps on debt; no commodity hedging disclosed

0

2

none in window

Unit sales of pharmaceutical and biologic products

Negotiated with rebates and tiered discounts

19.7% Gross Margin (Thin (<20%))

Product sales

Physician prescription, formulary placement, payer negotiation

Enterprise (health systems, government programs, managed care)

Government health programs (Medicare, Medicaid, VA)

Biopharmaceutical manufacturer & specialty distributor

Contract research and development services / collaboration partner

Moderate

Linear

International with significant U.S. focus

Very High

Low

Yes

High

Moderate

Moderate

No

High

4.9% Return on Assets (Excellent)

Defensive

Moderate

-19.73x Total Debt / Equity (Negative equity)

Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Sublinear

N-A

High

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.25 (HIL — ~25% of characteristic roles agent-automatable)

Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0001551152

ABBV

2.0% CapEx / Revenue (Low-CapEx Asset-Light)

Moderate

active_enforcement_matters,antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,capital_return_posture,channel_inventory_exposure,churn_vulnerability_index,currency_risk_exposure,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,cyber_framework_alignment,cyber_incident_materiality,cyber_oversight_body,data_sovereignty_risk,employee_headcount,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,hedging_program_scope,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,key_person_dependency,liquidity_sufficiency_assertion,marginal_cost_of_growth,market_structure,monetization_vector,named_competitors,network_effect_present,pricing_architecture,pricing_power_rating,product_revenue_concentration,purchase_commitment_rigidity,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,seasonality_pattern,supply_chain_dependency,switching_cost_profile,trade_restriction_exposure,vendor_lock_dependency_score

0

1

-32710

2026-08-14

2026-10-03T13:39|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

Not disclosed in filing

Not stated

Not explicitly named by company name

Fragmented

Skyrizi and Rinvoq combined = 42% of total net revenues in 2025

Dividend+Buyback; $11.7 billion dividends in 2025, $606 million share repurchases in 2025

Moderate; tariffs and trade policy risk to supply chains and costs

Mild; no significant seasonality disclosed

Affirmed

Moderate; three U.S. wholesale distributors control substantially all pharmaceutical sales

No specific named current consent orders or enforcement actions disclosed

Low; no material unconditional purchase commitments disclosed

No

NIST CSF

Audit Committee; full board reviews cybersecurity risks regularly

Moderate; Euro, Canadian dollar, Japanese yen, British pound primary exposures; approximately 24% of revenues outside U.S.

FX forwards on EUR, CAD, JPY, GBP revenues and net investment hedges; interest rate swaps on debt; no commodity hedging disclosed

0

2

none in window